Trials / Completed
CompletedNCT03251612
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
Predictive Value of In-vitro Testing Anti-cancer Therapy Sensitivity on Tumorspheres From Patients With Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Vejle Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the present study is to investigate the benefit of anti-cancer therapy administered on the basis of drug sensitivity testing. This concerns colorectal cancer patients who have previously received standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Based on sensitivity analysis | * 5FU, infusional * Capecitabine * Oxaliplatin (FOLFOX) * Irinotecan (FOLFIRI) * FOLFOXIRI (triplet) * Bevacizumab * Panitumumab * Cetuximab * Regorafenib * Tas-102 * Ramucirumab * Aflibercept * Pembrolizumab * Nivolumab * Vinorelbine and capecitabine * Sorafenib * Gemcitabine and capecitabine * Olaparib * Epirubicin |
Timeline
- Start date
- 2017-09-22
- Primary completion
- 2021-08-23
- Completion
- 2022-03-21
- First posted
- 2017-08-16
- Last updated
- 2023-01-18
Locations
4 sites across 2 countries: Denmark, Germany
Source: ClinicalTrials.gov record NCT03251612. Inclusion in this directory is not an endorsement.